Novo Nordisk A/S (NYSE:NVO) Shares Gap Up - What's Next?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $67.35, but opened at $70.81. Novo Nordisk A/S shares last traded at $70.65, with a volume of 2,548,211 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NVO. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Up 1.3%

The firm has a market capitalization of $311.71 billion, a P/E ratio of 21.11, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a fifty day simple moving average of $65.74 and a 200 day simple moving average of $82.29. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion during the quarter. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Finally, Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.